Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice

Cancer Genetics and Cytogenetics

Volumn 198, Issue 2, 2010, Pages 90-96

  Wu, De Dong ^a   Xiao, Yan Feng ^b   Geng, Yi ^a   Hou, Jie ^a  

^a Baoji Municipal Central Hospital   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; FAS ANTIGEN; FAS LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY INJURY; LIVER INJURY; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CARCINOMA; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OXIDES; STOMACH NEOPLASMS; SUBCUTANEOUS TISSUE; TRANSPLANTATION, HETEROTOPIC; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 77950877274     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.12.015     Document Type: Article

References (45)

1. Klaassen C.D. Heavy metals and heavy-metal antagonists 1996, McGraw-Hill, New York.
2. Aronson S.M. Arsenic and old myths. R I Med 1994, 77:233-234.
3. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., Shen Z.X., Sun G.L., Ma J., Zhang P., Zhang T.D., Gazin C., Naoe T., Chen S.J., Wang Z.Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia; As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
4. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., Wu W., Zhang F.Q., Chen Y., Zhou L., Li J.M., Zeng X.Y., Yang R.R., Yuan M.M., Ren M.Y., Gu F.Y., Cao Q., Gu B.W., Su X.Y., Chen G.Q., Xiong S.M., Zhang T.D., Waxman S., Wang Z.Y., Chen Z., Hu J., Shen Z.X., Chen S.J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
5. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., Stone R.M., Kalaycio M., Scheinberg D.A., Steinherz P., Sievers E.L., Coutré S., Dahlberg S., Ellison R., Warrell R.P. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
6. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
7. Konig A., Wrazel L., Warrell R.P., Rivi R., Pandolfi P.P., Jakubowski A., Gabrilove J.L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997, 90:562-570.
8. Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998, 12:1383-1391.
9. Li Y.M., Broome J.D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999, 59:776-780.
10. Ishitsuka K., Hanada S., Suzuki S., Utsunomiya A., Chyuman Y., Takeuchi S., Takeshita T., Shimotakahara S., Uozumi K., Makino T., Arima T. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998, 103:721-728.
11. Lu M., Levin J., Sulpice E., Sequeira-Le Grand A., Alemany M., Caen J.P., Han Z.C. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999, 27:845-852.
12. Rousselot P., Labaume S., Marolleau J.P., Larghero J., Noguera M.H., Brouet J.C., Fermand J.P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999, 59:1041-1048.
13. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Kim B.K., Lee Y.Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000, 60:3065-3071.
14. Dai J., Weinberg R.S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999, 93:268-277.
15. Akao Y., Nakagawa Y., Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase3 in vitro. FEBS Lett 1999, 455:59-62.
16. Ora I., Bondesson L., Jönsson C., Ljungberg J., Pörn-Ares I., Garwicz S., Pöhlman S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000, 277:179-185.
17. Nakagawa Y., Akao Y., Morikawa H., Hirata I., Katsu K., Naoe T., Ohishi N., Yagi K. Arsenic trioxide induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002, 70:2253-2269.
18. Liu L., Qin S., Chen H., Wang J., Ma J., Liu W. An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes. Chung Hua Kan Tsang Ping Tsa Chih 2000, 8:367-369.
19. Pu Y.S., Hour T.C., Chen J., Huang C.Y., Guan J.Y., Lu S.H. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002, 13:293-300.
20. Deng Y., Lin C., Zheng J., Fu M., Liang X., Chen J., Xiao P., Wu M. Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide. Chin Med J 2000, 113:84-88.
21. Um S.J., Lee S.Y., Kim E.J., Myoung J., Namkoong S.E., Park J.S. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett 2002, 181:11-22.
22. Vogt B.L., Rossman T.G. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts-a possible mechanism for arsenite's comutagenicity. Mutat Res 2001, 478:159-168.
23. Woo S.H., Park I.C., Park M.J., Lee H.C., Lee S.J., Chun Y.J., Lee S.H., Hong S.I., Rhee C.H. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002, 21:57-63.
24. Jiang X.H., Wong B.C., Yuen S.T., Jiang S.H., Cho C.H., Lai K.C., Lin M.C., Kung H.F., Lam S.K. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001, 91:173-179.
25. Zhang T.C., Cao E.H., Li J.F., Ma W., Qin J.F. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999, 35:1258-1263.
26. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 2003, 10:705-709.
27. Rojewski M.T., Körper S., Thiel E., Schrezenmeier H. Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. Oncol Rep 2004, 11:509-513.
28. Krammer P.H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B., et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994, 142:175-191.
29. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377:630-632.
30. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373:438-441.
31. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug induced apoptosis in leukemia cells. Nat Med 1996, 2:574-577.
32. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997, 57:3823-3829.
33. Nakamura S., Takeshima M., Nakamura Y., Ohtake S., Matsuda T. Induction of apoptosis in HL-60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 1997, 17:173-179.
34. Fulda S., Los M., Friesen C., Debatin K.M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998, 76:105-114.
35. Jing Q.Y., Niu B.H., Yu Z.J., Wang J.J. Expression of Bcl-2 and P53 protein in breast lesions. Di Si Jun Yi Da Xue Xue Bao (J Fourth Mil Med Univ) 2000, 21:1283-1285.
36. Xie Q.X., Wang H., Liao Y.R., Lin F.D., Li J.Y. Expression of Fas and FasL in 72 cases with transitional cell cancer of bladder. Cancer 2000, 19:156-158.
37. Liu Y.C.H., Lu Y., Qian H.X. Fas expression and tumor cell apoptosis in the poorly differentiated adenocarcinoma. Suzhou Univ J Med Sci 2003, 23:402-405.
38. Wang D.H., Wei H.L., Zhao H.S. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulation vital components in apoptotic pathway. Pharmacol Res 2005, 52:376-385.
39. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687.
40. Herst P.M., Hesketh E.L., Ritchie D.S., Berridge M.V. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60p0 cells. Leuk Res 2005, 32:327-333.
41. Cai H.S., Dend Z.H., Li S., Zhang X.R., Shen J.W. The study on arsenic trioxide induces apoptosis of human gastric SGC7901 cell. J Second Mil Med Univ 1999, 20:636-639.
42. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas (Apo-I/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
43. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?. Nat Med 1996, 2:1361-1366.
44. Walker P.R., Saas P., Dietrich P.Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998, 10:564-572.
45. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000, 14:1743-1750.